University of Virginia
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1819-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.virginia.edu
Clinical Trials
628
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (503 trials with phase data)• Click on a phase to view related trials
Developing Hyperpolarized Gas MRI Signatures to Detect and Manage Acute Cellular Rejection
- Conditions
- Lung Transplant Rejection
- Interventions
- Drug: Hyperpolarized Xe129
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 60
- Registration Number
- NCT07046910
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
weSIPsmarter: Evaluating a Digital Health Intervention Aimed at Reducing Sugary Drinks Among Rural Head Start Preschoolers and Their Parents
- Conditions
- Sugary Beverages
- First Posted Date
- 2025-07-01
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 744
- Registration Number
- NCT07046351
- Locations
- 🇺🇸
University of Virginia, Christiansburg, Virginia, United States
Meaning in Music-Based Pain Modulation
- Conditions
- The Focus of the Study is Healthy Volunteers
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 50
- Registration Number
- NCT07036315
Role of Estrogen on Skeletal Outcomes in FHA
- Conditions
- Bone StrengthBone DensityFHA (Functional Hypothalamic Amenorrhea)
- Interventions
- Drug: transdermal 17β-E2 with cyclic progestinDrug: oral 17β-E2 with cyclic progestinDrug: transdermal EE+LNG
- First Posted Date
- 2025-06-08
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 150
- Registration Number
- NCT07010146
- Locations
- 🇺🇸
University of Virginia Medical Center, Charlottesville, Virginia, United States
Tuberculosis in Rural and Malnourished Populations
- Conditions
- Tuberculosis (TB)Undernutrition
- First Posted Date
- 2025-05-14
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 360
- Registration Number
- NCT06971952
- Locations
- 🇹🇿
Haydom Lutheran Hospital, Haydom, Manyara, Tanzania
- Prev
- 1
- 2
- 3
- 4
- 5
- 126
- Next
News
University of Virginia Expands Manning Institute of Biotechnology with $66M Additional Contract
Skanska has secured an additional $66 million contract with the University of Virginia to construct the Paul and Diane Manning Institute of Biotechnology, bringing advanced translational research capabilities to the Commonwealth.
Ascidian Therapeutics Advances RNA Exon Editing Platform with Key Leadership Appointments and Clinical Progress
Ascidian Therapeutics has assembled a distinguished Scientific Advisory Board featuring globally recognized RNA biology experts to guide its RNA exon editing platform development.
UVA Launches $30M Trial to Test Ketamine for Life-Threatening Seizures
The University of Virginia has secured a $9.3 million NIH grant as initial funding for a $30 million clinical trial investigating ketamine's potential in treating status epilepticus, a life-threatening seizure condition.
UVA Initiates Clinical Trial of AI-Enhanced Automated Insulin Delivery System for Type 1 Diabetes
• The University of Virginia is launching a clinical trial to evaluate an AI-powered "Bolus Priming System with Reinforcement Learning" (BPS_RL) for automated insulin delivery in Type 1 diabetes patients. • The three-week trial will involve 16 adult participants testing the enhanced system, which integrates with existing AIDANET technology including a phone app, Dexcom glucose monitor, and Tandem insulin pump. • The innovative system aims to improve blood sugar control during meals and overnight without requiring user input, potentially reducing the burden of diabetes management.
Cannabinoids Show Promise in Managing Peripheral Neuropathy Symptoms
A systematic review of 14 clinical trials indicates that cannabis-based medicines may effectively treat peripheral neuropathy by reducing neuropathic pain.
Daratumumab/Lenalidomide Combo Improves MRD Negativity in Myeloma Maintenance
A post hoc analysis of the AURIGA trial reveals that adding daratumumab to lenalidomide enhances minimal residual disease (MRD)-negativity conversion rates in multiple myeloma patients post-transplant.